Jaktinib: all 41 studies that test it

Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• Jaktinib for Steroid-Refractory Acute Graft-Versus-Host DiseaseNot yet recruitingNCT07885228Phase 1/2
• An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07883382Phase 1/2
• Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).Not yet recruitingNCT07476872Phase 1/2
• Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With MyelofibrosisNot yet recruitingNCT07440654Not applicable
• Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line TherapyNot yet recruitingNCT07197112Phase 2
• Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsNot yet recruitingNCT07142837Phase 1/2
• Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerRecruitingNCT07080216Phase 1/2
• Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior TherapyRecruitingNCT07012304Phase 1/2
• Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruitingNCT06903377Phase 1/2
• Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaRecruitingNCT06883526Phase 1/2
• A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingNCT05688839Phase 2
• An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingNCT05686629Phase 2
• A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisRecruitingNCT05676242Phase 3
• A Safety and Tolerability Study of JaktinibRecruitingNCT05279001Phase 1
• A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.Not yet recruitingNCT04971551Phase 2
• A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.Active, not recruitingNCT07565597Phase 1
• A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy VolunteersCompletedNCT06246695Phase 1
• A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy ParticipantsCompletedNCT06193148Phase 1
• Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting ConditionsCompletedNCT06132243Phase 1
• Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)CompletedNCT05861128Phase 3
• Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)CompletedNCT05861102Phase 3
• Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)WithdrawnNCT05702788Phase 2
• Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.Status unknownNCT05672888Phase 2
• A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisActive, not recruitingNCT05526222Phase 3
• Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedNCT05255237Phase 3
• ADME Study of [14C]-Jaktinib in Healthy Male SubjectsCompletedNCT05150717Phase 1
• Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedNCT05051761Phase 3
• Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic FunctionCompletedNCT04993404Phase 1
• Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.TerminatedNCT04866056Phase 1/2
• Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.CompletedNCT04851535Phase 2
• Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk MyelofibrosisCompletedNCT04617028Phase 3
• A Phase 2 Study of Jaktinib in Participants With Moderate to Severe PsoriasisCompletedNCT04612699Phase 2
• Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic DermatitisCompletedNCT04539639Phase 2
• Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing SpondylitisCompletedNCT04507659Phase 2
• A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia AreataActive, not recruitingNCT04445363Phase 1/2
• Jaktinib Hydrochloride Cream For Atopic DermatitisCompletedNCT04435392Phase 1/2
• Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary FibrosisCompletedNCT04312594Phase 2
• Jaktinib for the Treatment of Ruxolitinib Intolerance of MyelofibrosisCompletedNCT04217993Phase 2
• Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia AreataCompletedNCT04034134Phase 2
• Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.CompletedNCT03886415Phase 2
• The Tolerance, Pharmacokinetics of Jaktinib in Healthy VolunteersCompletedNCT03314402Phase 1

← Jaktinib overview